5.2 RAAS Agents, Diuretics, Antiarrhythmics, Lipid-Lowering & Antithrombotic Drugs

RAAS Agents, Diuretics, Antiarrhythmics, Lipid-Lowering & Antithrombotic Drugs

Quick Answer: ACE inhibitors, ARBs, and diuretics primarily affect blood pressure with little direct effect on the exercise heart-rate response, but diuretics carry an important arrhythmia risk from electrolyte loss — highest in the post-exercise recovery window. Statins mainly threaten muscle tissue, not hemodynamics, and antiplatelets/anticoagulants mainly threaten bleeding safety, not the exercise response itself.

RAAS Agents: ACE Inhibitors & ARBs

ACE inhibitors ("-pril": lisinopril, enalapril, ramipril) block the conversion of angiotensin I to angiotensin II; angiotensin receptor blockers (ARBs) ("-sartan": losartan, valsartan) block the angiotensin II receptor directly. Both lower resting and exercise blood pressure through reduced vasoconstriction, with little to no direct effect on the heart-rate response to exercise — unlike beta-blockers, standard heart-rate-based intensity prescriptions remain valid for patients on these agents alone.

The main exercise-safety concern is exercise-associated or post-exercise hypotension, particularly early in a program or shortly after a dose increase — monitor blood pressure through the cool-down and caution patients about rapid postural changes. A useful chart-review distinguisher: ACE inhibitors cause a dry, nonproductive cough in a meaningful minority of patients (bradykinin-mediated); ARBs largely avoid this side effect. Don't mistake this cough for exercise-induced bronchospasm or a cardiac symptom during the patient interview. Aldosterone antagonists (spironolactone, eplerenone), often paired with these agents in heart failure, are potassium-sparing and raise hyperkalemia risk, especially with renal impairment.

Diuretics

Thiazides (hydrochlorothiazide, chlorthalidone), loop diuretics (furosemide, bumetanide), and potassium-sparing agents (spironolactone) reduce blood volume to lower blood pressure or manage fluid overload in heart failure. The central patient-safety concern is electrolyte depletion — especially hypokalemia and hypomagnesemia — which raises the risk of cardiac arrhythmia. This risk is not evenly distributed across a session: it is highest during the post-exercise recovery period, when serum potassium continues to decline after exercise-induced shifts, making unexplained palpitations or ectopy in recovery worth taking seriously in a diuretic-treated patient.

Diuretics also raise the risk of dehydration, hypovolemia, exercise-induced or orthostatic hypotension, and heat illness in warm environments. They have little direct effect on resting heart rate, but volume depletion can produce an exaggerated heart-rate response for a given workload. Encourage adequate hydration, and treat new cramps, palpitations, or dizziness as possible signs of an electrolyte imbalance worth reporting rather than routine fatigue.

Antiarrhythmics

This is a broad drug class (Vaughan-Williams classes I–IV), but amiodarone is the agent most CEPs will encounter, used for atrial fibrillation and ventricular arrhythmias. Amiodarone's long half-life and iodine content bring a distinct toxicity profile: pulmonary toxicity (roughly 10% of patients, more likely at higher cumulative doses and longer treatment duration — watch for new dyspnea, dry cough, or an unexplained drop in exercise tolerance) and thyroid dysfunction (either hypo- or hyperthyroid, requiring periodic TSH/T4 monitoring), along with photosensitivity and corneal deposits. A CEP who notices a gradual, otherwise-unexplained decline in a patient's functional capacity on amiodarone should consider — and report — a possible toxicity effect rather than assume simple deconditioning.

Lipid-Lowering: Statins

Statins (atorvastatin, simvastatin, rosuvastatin) have no direct effect on heart rate or blood pressure. Their exercise-relevant risk is muscular: statin-associated muscle symptoms (myalgia, weakness) affect a meaningful minority of patients, and rare but serious rhabdomyolysis (severe muscle breakdown with dark urine and marked CK elevation) can occur. New, unexplained, often bilateral muscle pain or weakness in a patient who recently started or increased a statin dose should be reported rather than dismissed as ordinary training soreness.

Antithrombotics: Antiplatelets & Anticoagulants

Antiplatelets (aspirin, clopidogrel, ticagrelor) and anticoagulants (warfarin, DOACs such as apixaban and rivaroxaban, heparin) have no direct hemodynamic effect on the exercise response. Their safety concern is increased bleeding and bruising risk — the exercise prescription should avoid contact/collision activities and high-fall-risk modes, with extra caution for balance-impaired patients (e.g., post-stroke) on anticoagulation. Watch for unusual bruising, hematuria, or dark stools as signs warranting physician follow-up.

Digoxin: A Special Case

Digoxin is used to control ventricular rate in atrial fibrillation and to manage symptoms in some heart failure patients. Two exam-relevant facts stand out. First, digoxin classically produces a "scooped" or coving ST-segment depression on the resting and exercise ECG that can mimic true ischemia — this is covered in detail later in this chapter, but it means an ST-segment change in a digoxin patient cannot automatically be read as a positive ischemia finding. Second, digoxin has a narrow therapeutic window, and toxicity risk rises sharply in the presence of hypokalemia — exactly the electrolyte disturbance a concurrent thiazide or loop diuretic can cause. Watch for classic toxicity signs (nausea, visual disturbances such as yellow-green halos, and new arrhythmias) in any patient on both a diuretic and digoxin, and treat this drug combination as one that warrants extra attention to electrolyte status.

Drug Class vs. Exercise Safety Concern